115 related articles for article (PubMed ID: 25131537)
1. Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.
Rondanin R; Simoni D; Romagnoli R; Baruchello R; Marchetti P; Costantini C; Fochi S; Padroni G; Grimaudo S; Pipitone RM; Meli M; Tolomeo M
Bioorg Med Chem Lett; 2014 Sep; 24(18):4568-4574. PubMed ID: 25131537
[TBL] [Abstract][Full Text] [Related]
2. Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Rondanin R; Simoni D; Maccesi M; Romagnoli R; Grimaudo S; Pipitone RM; Meli M; Cascio A; Tolomeo M
ChemMedChem; 2017 Aug; 12(15):1183-1190. PubMed ID: 28657677
[TBL] [Abstract][Full Text] [Related]
3. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Nelson EA; Walker SR; Weisberg E; Bar-Natan M; Barrett R; Gashin LB; Terrell S; Klitgaard JL; Santo L; Addorio MR; Ebert BL; Griffin JD; Frank DA
Blood; 2011 Mar; 117(12):3421-9. PubMed ID: 21233313
[TBL] [Abstract][Full Text] [Related]
4. STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells.
Gumus N; Gunduz C; Tezcanli Kaymaz B
J Biomol Struct Dyn; 2023 Jan; 41(1):186-199. PubMed ID: 34842047
[TBL] [Abstract][Full Text] [Related]
5. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
7. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Trécul A; Morceau F; Gaigneaux A; Orsini M; Chateauvieux S; Grandjenette C; Dicato M; Diederich M
Cancer Lett; 2013 Oct; 340(1):30-42. PubMed ID: 23811288
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
9. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
[TBL] [Abstract][Full Text] [Related]
11. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
14. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
[TBL] [Abstract][Full Text] [Related]
15. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
16. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
17. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
[TBL] [Abstract][Full Text] [Related]
18.
Sarno F; Pepe G; Termolino P; Carafa V; Massaro C; Merciai F; Campiglia P; Nebbioso A; Altucci L
Cells; 2020 Feb; 9(2):. PubMed ID: 32041350
[TBL] [Abstract][Full Text] [Related]
19. Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.
Wang X; Zeng J; Shi M; Zhao S; Bai W; Cao W; Tu Z; Huang Z; Feng W
DNA Cell Biol; 2011 Feb; 30(2):71-8. PubMed ID: 21091189
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
